COCRYSTAL PHARMA NEW O.N. (8CC) — Cash Flow-to-Debt Ratio
Latest as of December 2025:
-0.51x
COCRYSTAL PHARMA NEW O.N. (8CC) has a Cash Flow-to-Debt Ratio of -0.51x as of December 2025, meaning its operating cash flow of €-1.74 Million could theoretically repay -1% of its total liabilities (€3.38 Million) in one year. See COCRYSTAL PHARMA NEW O.N. free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.51x
Operating CF / Total Liabilities
Operating Cash Flow
€-1.74 Million
EUR
Total Liabilities
€3.38 Million
EUR
Data as of
Dec 2025
Most recent filing
COCRYSTAL PHARMA NEW O.N. Cash Flow-to-Debt Ratio (2021–2025)
Historical debt coverage capacity for COCRYSTAL PHARMA NEW O.N. across 5 annual periods. For the full cash flow conversion analysis, see 8CC cash flow conversion.
Annual Cash Flow-to-Debt Ratio for COCRYSTAL PHARMA NEW O.N. (2021–2025)
Year-by-year debt coverage analysis for COCRYSTAL PHARMA NEW O.N..
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.42x | €-8.19 Million | €3.38 Million | ▲ +42.2% |
| 2024 | -4.19x | €-16.48 Million | €3.93 Million | ▼ -39.3% |
| 2023 | -3.01x | €-14.67 Million | €4.88 Million | ▲ +82.1% |
| 2022 | -16.84x | €-21.43 Million | €1.27 Million | ▼ -144.0% |
| 2021 | -6.90x | €-12.72 Million | €1.84 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.